Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use
The present invention relates to a process, for the production of crystalline particles of an active organic compound The process includes the steps of generating a micro-seed by a wet-milling process and subjecting the micro-seed to a crystallization process. The resulting crystalline particles have a mean particle size of less than about 100 μm. The present invention also provides for a pharmaceutical composition which includes the crystalline particles produced by the method described herein and a pharmaceutically acceptable carrier.
1 . A process for the production of crystalline particles of an organic active compound comprising subjecting micro-seed to a crystallization process, wherein the micro-seed is generated by a wet milling process and has a mean particle size of about 0.1 to about 20 μm and wherein the resulting crystalline particles have a mean particle size less than 100 μm.
2 . The process of claim 1 , wherein the mean particle size of the resulting crystalline particles is less than 60 μm.
3 . The process of claim 1 , wherein the mean size of the micro-seed is approximately 0.5 to 20 μm.
4 . The process of claim 1 , wherein the mean size of the micro-seed is approximately 1 to 10 μm.
5 . The process of claim 1 , wherein a cavitation mill, a ball mill, a media mill, or sonication is utilized during the wet milling process.
6 . The process of claim 5 , wherein the media mill or ball media, utilizes 0.5 to 4 mm beads.
7 . The process of claim 6 , wherein a ceramic mill and ceramic beads are utilized or a chromium-lined mill and ceramic beads are utilized.
8 . The process of claim 1 , wherein the organic active compound is a pharmaceutical.
9 . The process of claim 8 , wherein the pharmaceutical is selected from the group consisting of analgesics, anti-inflammatory agents, antihelmintics, anti-arrthymics, anti-asthmatics, antibiotics, anticoagulants, antidepressants, antidiabetic agents, anti epileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, beta-adrenergic receptor blocking drugs, contrast media, corticosteroids, cough suppressants, diagnostic agents, diagnostic imaging agents, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants, sympathomimetics, thyroid agents, vasodilators and xanthines.
10 . A pharmaceutical composition comprising the crystalline particles produced in the process of claim 1 and a pharmaceutically acceptable carrier.
11 . The process of claim 1 , wherein the crystallization process comprises the following steps:
(1) generating a slurry of the micro-seed;
(2) generating a solution of the product to be crystallized; and
(3) combining the product of step (1) and the product of step (2).
12 . The process of claim 11 , wherein the crystallization process comprises using a batch, a semi-continuous or a continuous processing configuration.
13 . The process of claim 12 , wherein a recycle loop is utilized during the crystallization process.
14 . The process of claim 11 , wherein the solvent system of the crystallization process comprises primarily an aqueous solvent stream, primarily an organic solvent stream or a mixed solvent stream.
15 . The process of claim 11 , wherein a supplemental energy device is utilized during the cry stabilization process.
16 . The process of claim 15 , wherein the supplemental energy device is a mixing tee, a mixing elbow, a static mixer, a sonicator, or a rotor stator homogenizer.
17 . The process of claim 15 , wherein the supplemental energy device is utilized at the end of the crystallization process.
18 . The process of claim 15 , wherein the supplemental energy device is placed in a recycle loop.
19 . The process of claim 11 , wherein the crystallization process further comprises adding the micro-seed, a batch solution, a reagent solution, or an antisolvent into a recycle loop or a region of high mixing intensity.
20 . The process of claim 11 , wherein the crystallization process further comprises adding one or more supplemental additives.
21 . The process of claim 11 , wherein the slurry of the micro-seed and the solution of the product are rapidly micro-mixed when they are combined.
22 . The process of claim 1 , wherein the crystallization process comprises the following steps:
(1) generating a slurry of the micro seed using media milling;
(2) dissolving a portion of the micro-seed; and
(3) crystallizing the organic active compound on the micro-seed.
23 . The process of claim L wherein the resulting crystalline particle have a crystalline form that corresponds to the form of the micro-seed.